Oncternal Therapeutics (Oncternal Therapeutics) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Oncternal Therapeutics 3-Year Revenue Growth Rate?

Oncternal Therapeutics's Revenue per Share for the three months ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Oncternal Therapeutics was 92.30% per year. The lowest was -27.70% per year. And the median was 37.40% per year.

Competitive Comparison of Oncternal Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Oncternal Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncternal Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's 3-Year Revenue Growth Rate falls into.

Oncternal Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Oncternal Therapeutics (NAS:ONCT) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Oncternal Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncternal Therapeutics (Oncternal Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (NAS:ONCT) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

GTU:Germany

Address

12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130

Website

https://www.oncternal.com

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Executives

Gunnar F. Kaufmann	officer: Chief Scientific Officer	C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Salim Yazji	officer: Chief Medical Officer	12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
James B Breitmeyer	director, officer: President, CEO
Richard G Vincent	officer: Chief Financial Officer	C/O WOMEN FIRST HEALTH CARE, 5355 MIRA SORRENTO PLACE STE. 700, SAN DIEGO CA 92121-3825
Chase C. Leavitt	officer: General Counsel/Secretary	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Desimone	director	C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Rajesh Krishnan	officer: Chief Technology Officer	12230 EL CAMINO, SUITE 300, SAN DIEGO CA 92130
Jinzhu Phd Chen	director	12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Michael G Carter	director	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Daniel L Kisner	director	2292 FARADAY AVENUE, CARLSBAD CA 92008
Shanghai Pharmaceuticals Holding Co., Ltd.	10 percent owner	C/O ONCTEMAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Shanghai Pharmaceuticals (hk) Investment Ltd	10 percent owner	C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Shanghai Pharmaceutical (usa) Inc.	10 percent owner	C/O ONCTERNAL THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS ROAD #821, SAN DIEGO CA 92130-2122
Hazel M Aker	officer: General Counsel	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Man Cho	director	C/O ONCTERNAL THERAPEUTICS, INC., SUITE 300, SAN DIEGO CA 92130